Stock 000423 DONG-E-E-JIAO CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Dong-E-E-Jiao Co.,Ltd.

Equities

000423

CNE0000006Y9

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-04-25 EDT 		5-day change 1st Jan Change
66.6 CNY -1.70% Intraday chart for Dong-E-E-Jiao Co.,Ltd. -4.13% +35.04%
04-25 Dong-E-E-Jiao Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-12 Dong-E-E-Jiao Forecasts Up to 55% Jump in Q1 Profit MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 22,914 24,928 31,394 26,210 31,761 42,889 - -
Enterprise Value (EV) 1 20,992 23,480 28,164 20,864 25,956 38,155 37,774 37,089
P/E ratio -52 x 553 x 71.7 x 33.6 x 27.6 x 30.9 x 26.5 x 21.9 x
Yield 0.57% 0.77% 1.33% 2.85% 3.61% 2.99% 2.91% 3.3%
Capitalization / Revenue 7.74 x 7.31 x 8.16 x 6.48 x 6.74 x 7.67 x 6.62 x 5.64 x
EV / Revenue 7.1 x 6.89 x 7.32 x 5.16 x 5.5 x 6.82 x 5.83 x 4.88 x
EV / EBITDA -56.9 x 75 x 38.8 x 19.6 x 17.3 x 23.2 x 19.4 x 15.9 x
EV / FCF -14,416,497 x 33,557,131 x - - - - - -
FCF Yield -0% 0% - - - - - -
Price to Book 2.32 x 2.6 x 3.15 x 2.58 x 2.96 x 3.92 x 3.79 x 3.6 x
Nbr of stocks (in thousands) 647,847 643,977 643,977 643,977 643,977 643,977 - -
Reference price 2 35.37 38.71 48.75 40.70 49.32 66.60 66.60 66.60
Announcement Date 20-03-26 21-03-19 22-03-25 23-03-24 24-03-21 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,959 3,409 3,849 4,042 4,715 5,592 6,484 7,601
EBITDA 1 -368.7 313 725.6 1,065 1,504 1,643 1,950 2,335
EBIT 1 -513.1 152.1 568.8 914.9 1,360 1,591 1,883 2,275
Operating Margin -17.34% 4.46% 14.78% 22.64% 28.85% 28.45% 29.05% 29.93%
Earnings before Tax (EBT) 1 -505.2 165.7 571.1 912 1,363 1,643 1,916 2,316
Net income 1 -443.9 43.29 440.4 780 1,151 1,392 1,625 1,964
Net margin -15% 1.27% 11.44% 19.3% 24.41% 24.89% 25.07% 25.85%
EPS 2 -0.6800 0.0700 0.6800 1.210 1.790 2.158 2.515 3.044
Free Cash Flow -1,456 699.7 - - - - - -
FCF margin -49.22% 20.52% - - - - - -
FCF Conversion (EBITDA) - 223.56% - - - - - -
FCF Conversion (Net income) - 1,616.35% - - - - - -
Dividend per Share 2 0.2000 0.3000 0.6500 1.160 1.780 1.994 1.937 2.200
Announcement Date 20-03-26 21-03-19 22-03-25 23-03-24 24-03-21 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 1,023 890.4 935.4 1,221 995.3 1,069 - 1,261 1,287 1,453 1,290 1,498 1,513 1,492 1,511
EBITDA 1 230.9 159.3 197.6 299.6 - - - - - - 364.9 425.5 425.5 440.4 440.4
EBIT 1 201.6 157.1 198.6 268.5 290.8 279 - 312.1 400.3 409.9 348.3 408.8 408.8 417.2 417.2
Operating Margin 19.71% 17.65% 21.23% 21.99% 29.22% 26.1% - 24.75% 31.1% 28.2% 27.01% 27.3% 27.03% 27.97% 27.61%
Earnings before Tax (EBT) 1 200.8 158.2 198.9 265.7 289.1 278.8 - 307.1 407.7 412.2 377.2 442.8 442.8 445.3 445.3
Net income 1 139.2 114.7 193.6 204.6 267.1 230.3 - 252.6 367.2 353.4 318.5 373.9 373.8 376 376
Net margin 13.6% 12.88% 20.69% 16.77% 26.84% 21.55% - 20.03% 28.53% 24.32% 24.7% 24.96% 24.72% 25.21% 24.88%
EPS 2 0.2100 0.1781 0.3000 0.3200 0.4100 0.3577 0.4600 0.4000 0.5700 0.5488 0.4870 0.5716 0.5716 0.5749 0.5749
Dividend per Share 2 - - - - - - - - - - 1.935 - - - 1.269
Announcement Date 22-03-25 22-04-28 22-08-19 22-10-30 23-03-24 23-04-25 23-08-25 23-10-30 24-03-21 24-04-25 - - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 1,922 1,448 3,230 5,346 5,805 4,734 5,115 5,800
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow -1,456 700 - - - - - -
ROE (net income / shareholders' equity) -4.13% 0.44% 4.47% 7.68% 11.1% 12.6% 14.3% 16.5%
ROA (Net income/ Total Assets) -3.48% 0.38% 3.9% - - 10.2% 11.5% 12.7%
Assets 1 12,764 11,332 11,293 - - 13,692 14,106 15,468
Book Value Per Share 2 15.30 14.90 15.50 15.80 16.60 17.00 17.60 18.50
Cash Flow per Share 2 -1.710 1.220 4.350 3.280 3.030 1.490 3.020 2.830
Capex 1 330 101 24.7 45.5 46.6 138 129 146
Capex / Sales 11.16% 2.97% 0.64% 1.13% 0.99% 2.47% 1.99% 1.92%
Announcement Date 20-03-26 21-03-19 22-03-25 23-03-24 24-03-21 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Dong-E-E-Jiao Co.,Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
66.6 CNY
Average target price
68.46 CNY
Spread / Average Target
+2.80%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Alternative Medicine

1st Jan change Capi.
DONG-E-E-JIAO CO.,LTD. Stock Dong-E-E-Jiao Co.,Ltd.
+35.04% 5.92B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD. Stock Shijiazhuang Yiling Pharmaceutical Co., Ltd.
-15.13% 4.51B
TASLY PHARMACEUTICAL GROUP CO., LTD Stock Tasly Pharmaceutical Group Co., Ltd
-9.75% 3.15B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED Stock Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
+2.14% 3.1B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. Stock Shandong Buchang Pharmaceuticals Co., Ltd.
-6.82% 2.42B
HENAN LINGRUI PHARMACEUTICAL CO., LTD. Stock Henan Lingrui Pharmaceutical Co., Ltd.
+47.87% 1.97B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD. Stock Tibet Cheezheng Tibetan Medicine Co., Ltd.
+0.09% 1.65B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD. Stock GuangYuYuan Chinese Herbal Medicine Co., Ltd.
-7.89% 1.68B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD Stock Tianjin Chase Sun Pharmaceutical Co.,Ltd
-12.97% 1.53B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD Stock Zhejiang Jolly Pharmaceutical Co.,LTD
+33.40% 1.38B
Alternative Medicine
  1. Stock Market
  2. Equities
  3. 000423 Stock
  4. Financials Dong-E-E-Jiao Co.,Ltd.